CYTER915
Cancer Immunotherapy
DiscoveryActive
Key Facts
About FibroBiologics
FibroBiologics is a clinical-stage biotech focused on developing fibroblast cell-based therapies for chronic diseases, positioning fibroblasts as a superior alternative to mesenchymal stem cells. The company has established a robust intellectual property portfolio of over 270 patents and has achieved an FDA IND clearance for its lead program in Degenerative Disc Disease. Its strategy hinges on demonstrating clinical proof-of-concept for its fibroblast platform across multiple high-need indications to validate its core technological thesis and unlock significant value.
View full company profileTherapeutic Areas
Other Cancer Immunotherapy Drugs
| Drug | Company | Phase |
|---|---|---|
| Immuno-Oncology | Resolve Biosciences | Research-Use |
| In vivo CAR-T Program | Deliver Biosciences | Pre-clinical |
| Novel Target Discovery | Noetik | Discovery |
| YB328 Microbiome Program | ARC Therapies | Research |
| Engineered Cancer Exosomes (HLA‑G Targeted) | Esco Aster | Preclinical |